Protective role of fructokinase blockade in the pathogenesis of acute kidney injury in mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model (in vivo knockout and pharmacological mouse study)
PubMed 28194018 · doi:10.1038/ncomms14181
What was done
Researchers investigated the role of endogenous fructose production through the polyol pathway and fructokinase metabolism in mouse models of ischemic acute kidney injury (iAKI). They assessed polyol pathway markers (aldose reductase, sorbitol, and endogenous fructose) in the kidney cortex, compared outcomes between wild-type and fructokinase knockout mice, and tested the therapeutic effect of the fructokinase inhibitor luteolin in wild-type mice.
What was found
The abstract reports directional findings without numerical values. In mice subjected to iAKI, the renal cortical polyol pathway was activated with elevated aldose reductase, sorbitol, and endogenous fructose. Wild-type mice experienced severe renal injury, ATP depletion, increased uric acid, oxidative stress, and inflammation, whereas fructokinase knockout mice did not develop this severe injury. Administering luteolin to wild-type mice significantly ameliorated iAKI-induced renal injury and dysfunction.
Why it matters
These findings identify endogenous renal fructose generation and fructokinase activity as pathogenic mediators of ischemic acute kidney injury, highlighting fructokinase blockade as a potential therapeutic strategy.
Limits
The findings derive almost entirely from mouse models of ischemic injury, which may not replicate the complex multifactorial etiology of human acute kidney injury. The abstract does not provide exact sample sizes, quantitative effect estimates, or details regarding the human patient observations mentioned.
Cited by
- supports Flavonoids including luteolin, quercetin, astilbin, and compounds in mangosteen directly block fructose metabolism.